FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

被引：0
|
作者：
Le, Xiuning
Spira, Alexander I.
Gadgeel, Shirish M.
Riess, Jonathan W.
Yu, Yan
Zhao, Yanqiu
Cheng, Ying
Juan-Vidal, Oscar
Gao, Bo
Yoh, Kiyotaka
Forster, Martin
Kitazono, Satoru
Hayashi, Hidetoshi
Planchard, David
Jiang, Yong
Baio, Nichole
Kowanetz, Marcin
Leung, William
Hsu, Jerry Y.
Wang, Jie
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] NEXT Oncol Virginia, Fairfax, VA USA
[3] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA
[4] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[5] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Jilin Canc Hosp, Changchun, Peoples R China
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Blacktown Hosp, Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[10] Natl Canc Ctr Hosp East, Kashiwa, Japan
[11] UCL, Hosp NHS Trust, Canc Inst, London, England
[12] Japanese Fdn Canc Res JFCR, Canc Inst Hosp, Tokyo, Japan
[13] Kindai Univ Hosp, Osaka, Japan
[14] Gustave Roussy, Dept Med Oncol, Thorac Grp, Villejuif, France
[15] Allist Pharmaceut, Shanghai, Peoples R China
[16] ArriVent Biopharma, Newtown, PA USA
[17] ArriVent Biopharma, Burlingame, CA USA
[18] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8666
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)
    Okuma, Yusuke
    Shimokawa, Mototsugu
    Hashimoto, Kana
    Mizutani, Hideaki
    Wakui, Hiroshi
    Murakami, Shuji
    Atagi, Shinji
    Minato, Koichi
    Seike, Masahiro
    Ohe, Yuichiro
    Kubota, Kaoru
    FUTURE ONCOLOGY, 2022, 18 (05) : 523 - 531
  • [32] Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
    Popat, Sanjay
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Park, Cheol Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Marten, Angela
    Miura, Satoru
    ONCOLOGIST, 2022, 27 (04): : 255 - 265
  • [33] Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
    Fan, Y.
    Chen, K.
    Xu, Y.
    Huang, Z.
    Hong, W.
    Li, H.
    Xie, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S352 - S352
  • [34] The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
    Yan, Ningning
    Guo, Sanxing
    Huang, Siyuan
    Zhang, Huixian
    Li, Xingya
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
    Wang, Chunsheng
    Zhao, Kewei
    Hu, Shanliang
    Dong, Wei
    Gong, Yan
    Li, Minghuan
    Xie, Conghua
    LUNG CANCER, 2022, 172 : 86 - 93
  • [36] A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
    Han, B.
    Zhou, C.
    Zheng, W.
    Wu, L.
    Ma, Z.
    Wang, H.
    Yu, X.
    Ding, G.
    Ma, D.
    Nie, L.
    Zhang, Z.
    Dong, X.
    Shang, Y.
    Tang, K.
    Zhang, W.
    Hsu, J. Y.
    Jiang, Y.
    Zhao, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S49 - S49
  • [37] Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
    Fang, W. F.
    Bu, Q.
    Wang, Q. M.
    Zhao, W. H.
    Wang, L. P.
    Dong, X. R.
    Chen, P. F.
    Wen, Z. B.
    Jia, J.
    Jiang, G. M.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S333 - S334
  • [38] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
    Shi, Jinpeng
    Yang, Hui
    Jiang, Tao
    Li, Xuefei
    Zhao, Chao
    Zhang, Limin
    Zhao, Sha
    Liu, Xiaozhen
    Jia, Yijun
    Wang, Yan
    Xi, Lei
    Zhang, Shijia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (06) : 543 - +
  • [39] Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations
    Wu, L.
    Pu, X.
    Zhou, Y.
    Kong, Y.
    Chen, B.
    Yang, A.
    Li, J.
    Li, K.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1695 - S1695
  • [40] Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
    Fang, W.
    Bu, Q.
    Wang, Q.
    Zhao, W.
    Wang, L.
    Dong, X.
    Chen, P.
    Wen, Z.
    Jia, J.
    Jiang, G.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1588
12345